


Roledumab (LFB) Preclinical studies

- IgG1 antibody, directed against RhD epitope not present on DVI, DFR, DHAR and DHMI
Béliard et al. Brit J Haematol 2008; 141:109-19
- Increased affinity to FcγRIIIa compared to polyclonal anti-D due to low Fc-fucosylation
Increased ADCC by NK cells compared to polyclonal anti-D
FcRn mediated binding and transport similar to polyclonal anti-D
Siberil et al. Clin Immunol 2006;118:170-9
- RBC clearance in NOD-SCID mice similar to polyclonal anti-D (*Siberil et al. 2006*)
- Purity and dimers investigated (*Rouby et al. Mabs 2020; 12:e1781743*)

Roledumab (Phase 1)

- Autologous RBC clearance in D-pos male
(Béliard et al. Brit J Haematol 2008; 141:109-19)



at least as potent as the polyclonal anti-D

- In vivo safety studies (*Yver et al. Vox Sang 2012; 103:213-22*)
 - Pharmacokinetic profile similar to that of polyclonal anti-D
 - Safe and well tolerated in 46 D neg volunteers

Prophylaxis studies (Phase 2 and 3)

- **Phase 2** in 78 healthy male volunteers (*protocol at clinicaltrials.gov ADNC-0726=NCT0095257 (2009-2011)*)
 - Roledumab exhibits a faster RhD-positive RBC clearance than plasma anti-D (IV and IM 300µg dose)



- **Phase 2B** studies in 62 pregnant women (IM 300µg group (n=26) – IV 300µg group (n=36)) ((ADNC-1301=NCT02287896) (study submitted 10/2014)

All PK results and safety data published at *clinicaltrials.gov* (last results submitted 7/2020)



- **Phase 3** trial:
 - Clinical trial planned in >1000 pregnant

However:

Despite good results in Phase 2 and 2B studies, no Phase 3 trial has been started